Published in Int J Cancer on November 01, 2010
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia (2016) 0.93
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
Novel immune modulators used in hematology: impact on NK cells. Front Immunol (2013) 0.89
Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther (2015) 0.85
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia (2016) 0.84
Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia. Oncotarget (2016) 0.82
Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity. Int J Mol Sci (2012) 0.78
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res (2014) 0.78
Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment. Leukemia (2013) 0.77
Protein Kinase Inhibitors CK59 and CID755673 Alter Primary Human NK Cell Effector Functions. Front Immunol (2013) 0.75
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunol Immunother (2016) 0.75
The role of natural killer cells in chronic myeloid leukemia. Rev Bras Hematol Hemoter (2011) 0.75
Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph(+) leukemia patients treated with dasatinib. Leukemia (2016) 0.75
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50
Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica (2003) 2.17
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood (2003) 1.99
Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest (2004) 1.89
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol (2005) 1.85
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 1.83
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res (2005) 1.82
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood (2009) 1.79
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol (2006) 1.74
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res (2006) 1.68
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res (2003) 1.60
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood (2004) 1.56
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain (2006) 1.54
Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol (2005) 1.54
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood (2007) 1.54
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol (2006) 1.37
Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res (2009) 1.34
Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol (2006) 1.34
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood (2003) 1.32
Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol (2012) 1.30
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol (2002) 1.29
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood (2006) 1.27
Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res (2009) 1.25
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23
Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res (2011) 1.21
Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 1.21
CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells (2004) 1.20
Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol (2008) 1.20
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res (2005) 1.19
The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol (2007) 1.18
hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood (2007) 1.13
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol (2009) 1.12
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother (2006) 1.11
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer (2009) 1.11
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer (2010) 1.11
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J (2007) 1.11
Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res (2011) 1.10
Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res (2007) 1.10
PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood (2005) 1.09
TLR ligands differentially affect uptake and presentation of cellular antigens. Blood (2007) 1.08
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res (2008) 1.08
Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun (2008) 1.07
CLEC2A: a novel, alternatively spliced and skin-associated member of the NKC-encoded AICL-CD69-LLT1 family. Immunogenetics (2007) 1.04
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res (2007) 1.03
Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int J Med Microbiol (2009) 1.03
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer (2013) 1.03
Interaction of C-type lectin-like receptors NKp65 and KACL facilitates dedicated immune recognition of human keratinocytes. Proc Natl Acad Sci U S A (2010) 1.02
Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res (2007) 0.99
Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res (2004) 0.98
Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol (2002) 0.98
Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther (2006) 0.97
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood (2003) 0.97
Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun (2011) 0.97
A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol (2013) 0.95
Vis-à-vis in the NKC: genetically linked natural killer cell receptor/ligand pairs in the natural killer gene complex (NKC). J Innate Immun (2011) 0.95
Identification of a lysosomal peptide transport system induced during dendritic cell development. J Biol Chem (2007) 0.95
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood (2002) 0.94
Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia. Blood (2009) 0.93
NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood (2008) 0.93
Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood (2008) 0.92
Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity. J Immunol (2010) 0.92
Modulation of NK cell function by genetically coupled C-type lectin-like receptor/ligand pairs encoded in the human natural killer gene complex. Front Immunol (2013) 0.91
Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res (2009) 0.91
RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia. Cancer Res (2012) 0.90
The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol (2006) 0.89
Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res (2004) 0.89
Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. PLoS Pathog (2010) 0.89
Conserved amino acids within the adenovirus 2 E3/19K protein differentially affect downregulation of MHC class I and MICA/B proteins. J Immunol (2009) 0.88
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother (2011) 0.88
Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains. J Immunol (2006) 0.88
Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol (2010) 0.87
Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res (2008) 0.87
Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res (2007) 0.86
Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol (2003) 0.85
Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. Med Microbiol Immunol (2008) 0.85
Genetically coupled receptor-ligand pair NKp80-AICL enables autonomous control of human NK cell responses. Blood (2013) 0.83
Activated CD8+ T lymphocytes induce differentiation of monocytes to dendritic cells and restore the stimulatory capacity of interleukin 10-treated antigen-presenting cells. Cancer Res (2002) 0.83
Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res (2003) 0.82
An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. Int J Cancer (2014) 0.82